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Research Letter to the Editor 31	  
To the Editor: 32	  
 The diagnosis of pulmonary tuberculosis in HIV-infected individuals is particularly 33	  
challenging, as HIV-induced alterations of the immune system lead to reduced cavitations, 34	  
limiting the sensitivity of sputum-based assays (1). Thus, alternate markers are needed to 35	  
distinguish between latent (LTBI) and active TB (aTB) in this high-risk group. Several 36	  
attributes of Mtb-specific CD4+ T cells have been shown to efficiently delineate LTBI and 37	  
aTB in HIV-uninfected individuals, including their polyfunctional or memory profiles (2-4). 38	  
Moreover, Adekambi et al. recently demonstrated that the activation profile of Mtb-specific 39	  
CD4+ T cells accurately discriminates between LTBI and aTB (5). As chronic HIV infection 40	  
is characterized by persistent systemic immune activation	  (6), it is plausible that these blood-41	  
based markers may not be relevant for HIV-infected individuals.  42	  
 We therefore compared the potential of the activation and polyfunctional profiles of 43	  
Mtb-specific CD4+T cells to distinguish between LTBI and aTB in HIV-uninfected and HIV-44	  
infected individuals. We analyzed 76 participants divided in four groups according to their 45	  
TB and HIV status (Table S1): LTBI/HIV- (n=17), aTB/HIV- (n=17), LTBI/HIV+ (n=21, 46	  
median CD4 count: 316 cells/mm3, IQR: 231-543) and aTB/HIV+ (n=21, CD4 count: 250 47	  
cells/mm3, IQR: 155-295). LTBI was defined as TST positive, IGRA positive, sputum culture 48	  
negative and normal CXR. aTB was diagnosed based on symptoms suggestive of tuberculosis 49	  
and Mtb positive smear and/or sputum culture, as previously described (7). All HIV-infected 50	  
participants were ART-naïve. UCT ethics committee approved the study and written consent 51	  
was obtained from participants. Cryopreserved PBMCs were stimulated for 16 hours with 52	  
ESAT-6/CFP-10 peptide pool and intracellular staining using a live/dead marker and 53	  
antibodies towards CD3, CD4, CD8, HLA-DR, Ki67, CD38, IFN-γ, TNF-α and IL-2 was 54	  
performed. Positive ESAT-6/CFP-10 responses (defined as twice the background) were 55	  
detectable in 16 subjects in the LTBI/HIV- and LTBI/HIV+ groups; and in 15 and 18 56	  
individuals in the aTB/HIV- and aTB/HIV+ groups, respectively. No significant differences 57	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were observed in the overall magnitude of IFNγ+ responses between the four groups (data not 58	  
shown).  59	  
 We first compared the activation profile of IFNγ+ Mtb-specific CD4+T cells between 60	  
the four groups (Figure 1A). As previously shown (5), in HIV-uninfected persons, HLA-DR, 61	  
Ki67 and CD38 expression on IFNγ+ Mtb-specific CD4+T cells were significantly higher in 62	  
aTB participants when compared to LTBI (Figure 1B). Interestingly, while HLA-DR 63	  
expression on Mtb-specific CD4+T cells in the LTBI/HIV+ group (median 41.7%, IQR: 25.7-64	  
54.6) was significantly higher when compared to the LTBI/HIV- group (13.7%, IQR: 8.9-65	  
27.5), HLA-DR expression on these cells was significantly further increased in HIV-infected 66	  
individuals with aTB (84%, IQR: 73.7-87.9) (Figure 1B). Additional analyses showed that in 67	  
LTBI/HIV+ individuals, HLA-DR expression on Mtb-specific CD4+T cells mirrors HLA-DR 68	  
expression in the whole CD4 compartment (p=0.02, r=0.56), but this association was not 69	  
apparent in aTB/HIV+ individuals (data not shown). Unlike HLA-DR, Ki67 and CD38 70	  
expression levels were comparable between HIV-uninfected and HIV-infected individuals 71	  
with LTBI. In HIV-infected persons with aTB, Ki67 expression on IFNγ+ Mtb-specific 72	  
CD4+T cells was significantly higher (p<0.0001) when compared to LTBI, while the up-73	  
regulation of CD38 was more modest between these two groups (p=0.03). Of note, in the 74	  
aTB/HIV+ group, the expression of CD38 was significantly higher in individuals with a 75	  
positive smear when compared to smear negative (p=0.01, data not shown), suggesting that 76	  
CD38 expression could reflect bacterial load. To assess the accuracy of these markers to 77	  
discriminate between LTBI and aTB status, ROC curves and cross-over plots were performed. 78	  
Figure 1C shows the data for HLA-DR, AUC and p-values reflect that HLA-DR expression 79	  
on IFNγ+ Mtb-specific CD4+T cells distinguishes LTBI and aTB in both the HIV- and HIV+ 80	  
groups (AUC=0.98, p<0.0001; AUC=0.9, p<0.0001, respectively). However, the optimum 81	  
cutoff values discriminating LTBI from aTB were distinct for HIV-uninfected (40%) and 82	  
HIV-infected individuals (70%). In our experimental setting, the expression of Ki67 and 83	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CD38 were less robust to differentiate TB status in HIV-uninfected (AUC=0.896, p=0.00017, 84	  
cutoff=1.4% and AUC=0.858, p=0.0007, cutoff=4%, respectively) and in HIV-infected 85	  
individuals (AUC=0.89, p=0.0002, cutoff=2.4% and AUC=0.72, p=0.026, cutoff=5%, 86	  
respectively) (data not shown). Our data were comparable to (5), despite disparity in the 87	  
cutoff value for these markers, which could be explained by flow-cytometry technical 88	  
differences.  89	  
 The polyfunctional profile of Mtb-specific CD4+T cells has also been shown to 90	  
discriminate between LTBI and aTB in HIV-uninfected individuals	  (2, 3), but conflicting data 91	  
exists for HIV-infected persons (8-10). Thus, we compared the profile of ESAT-6/CFP-10-92	  
specific CD4+T cells, based on their capacity to secrete IFN-γ, TNF-α and/or IL-2, between 93	  
the four groups (Figure 2A). HIV-uninfected individuals with LTBI were characterized by a 94	  
predominant proportion of IFNγ+IL2+TNFα+ cells (median: 44%, IQR: 35-49), a subset that 95	  
was significantly lower in individuals with HIV (20%, IQR: 15-32), aTB (16%, IQR: 4-19) or 96	  
both (9%, IQR: 2.6-22) (Figure 2B). In participants with HIV and/or aTB, IFNγ+ IL2-TNFα+ 97	  
cells counterweighed the reduction of triple positive cells. Of note, unlike previously reported 98	  
(2), no differences in the proportion of TNF-α single positive Mtb-specific CD4+ T cells were 99	  
observed, these differences could arise from significant disparities in the age, ethnicity and 100	  
TB diagnosis in the study cohorts. ROC curve analyses (Figure 2C) show that the proportion 101	  
of IFNγ+IL2+TNFα+ or IFNγ+IL2-TNFα+ Mtb-specific CD4+T cells allowed the distinction 102	  
between LTBI and aTB in HIV-uninfected individuals (AUC=0.97, p<0.0001 and AUC=0.92, 103	  
p<0.0001, respectively) but not in HIV-infected persons.  104	  
 In summary, these data show that HLA-DR expression level on IFNγ+ Mtb-specific 105	  
CD4+T cells represents a robust marker to distinguish between LTBI and aTB in both HIV-106	  
uninfected and ART naïve HIV-infected individuals. This suggests that despite HIV-induced 107	  
systemic immune activation, active bacterial replication promotes further up-regulation of 108	  
HLA-DR on Mtb-specific CD4+T cells. On the contrary, the polyfunctional profile of Mtb-109	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specific CD4+T cells associated with TB status solely in HIV-uninfected individuals, 110	  
suggesting that HIV infection may alter the secretion potential and/or localization of Mtb-111	  
specific CD4+T cells even in the absence of bacterial replication. One main limitation of such 112	  
assays, requiring cell stimulation to identify Mtb-specific CD4+T cells, is that the analysis is 113	  
restricted to individuals with detectable Mtb responses. Inclusion of additional 114	  
immunodominant Mtb antigens could improve the “coverage” of Mtb responders. Further 115	  
experiments will be needed to confirm these data in larger study including HIV-infected 116	  
participants on antiretroviral treatment. Nevertheless, this study confirms that HLA-DR 117	  
expression could represent an important alternate tool to assess TB status in HIV-uninfected 118	  
individuals and expand this finding to HIV-infected subjects. 119	  
 120	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References: 122	  
1. Gardiner JL, Karp CL. Transformative tools for tackling tuberculosis. J Exp Med 2015; 123	  
212: 1759-1769. 124	  
2. Harari A, Rozot V, Bellutti Enders F, Perreau M, Stalder JM, Nicod LP, Cavassini M, 125	  
Calandra T, Blanchet CL, Jaton K, Faouzi M, Day CL, Hanekom WA, Bart PA, Pantaleo 126	  
G. Dominant TNF-alpha+ Mycobacterium tuberculosis-specific CD4+ T cell responses 127	  
discriminate between latent infection and active disease. Nat Med 2011; 17: 372-376. 128	  
3. Lichtner M, Mascia C, Sauzullo I, Mengoni F, Vita S, Marocco R, Belvisi V, Russo G, 129	  
Vullo V, Mastroianni CM. Multifunctional Analysis of CD4(+) T-Cell Response as 130	  
Immune-Based Model for Tuberculosis Detection. J Immunol Res 2015; 2015: 217287. 131	  
4. Portevin D, Moukambi F, Clowes P, Bauer A, Chachage M, Ntinginya NE, Mfinanga E, 132	  
Said K, Haraka F, Rachow A, Saathoff E, Mpina M, Jugheli L, Lwilla F, Marais BJ, 133	  
Hoelscher M, Daubenberger C, Reither K, Geldmacher C. Assessment of the novel T-cell 134	  
	   6	  
activation marker-tuberculosis assay for diagnosis of active tuberculosis in children: a 135	  
prospective proof-of-concept study. Lancet Infect Dis 2014; 14: 931-938. 136	  
5. Adekambi T, Ibegbu CC, Cagle S, Kalokhe AS, Wang YF, Hu Y, Day CL, Ray SM, 137	  
Rengarajan J. Biomarkers on patient T cells diagnose active tuberculosis and monitor 138	  
treatment response. J Clin Invest 2015; 125: 3723. 139	  
6. Paiardini M, Muller-Trutwin M. HIV-associated chronic immune activation. Immunol Rev 140	  
2013; 254: 78-101. 141	  
7. Kaforou M, Wright VJ, Oni T, French N, Anderson ST, Bangani N, Banwell CM, Brent AJ, 142	  
Crampin AC, Dockrell HM, Eley B, Heyderman RS, Hibberd ML, Kern F, Langford PR, 143	  
Ling L, Mendelson M, Ottenhoff TH, Zgambo F, Wilkinson RJ, Coin LJ, Levin M. 144	  
Detection of tuberculosis in HIV-infected and -uninfected African adults using whole 145	  
blood RNA expression signatures: a case-control study. PLoS Med 2013; 10: e1001538. 146	  
8. Pollock KM, Whitworth HS, Montamat-Sicotte DJ, Grass L, Cooke GS, Kapembwa MS, 147	  
Kon OM, Sampson RD, Taylor GP, Lalvani A. T-cell immunophenotyping distinguishes 148	  
active from latent tuberculosis. J Infect Dis 2013; 208: 952-968. 149	  
9. Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, Pinnetti C, Sampaolesi A, Antinori A, 150	  
Girardi E, Goletti D. Polyfunctional T-cells and effector memory phenotype are associated 151	  
with active TB in HIV-infected patients. J Infect 2014; 69: 533-545. 152	  
10. Canaday DH, Sridaran S, Van Epps P, Aung H, Burant CJ, Nsereko M, Mayanja-Kizza H, 153	  
Betts MR, Toossi Z. CD4+ T cell polyfunctional profile in HIV-TB coinfection are similar 154	  
between individuals with latent and active TB infection. Tuberculosis (Edinb) 2015; 95: 155	  
470-475. 156	  157	  
	   7	  
LEGENDS: 158	  
Figure 1. Comparison of the activation profile of IFNγ+ ESAT-6/CFP-10-specific CD4+ T 159	  
cells between HIV-uninfected and HIV-infected individuals with latent or active TB disease. 160	  
(A) Representative overlay plots of HLA-DR, CD38 and Ki-67 expression in total CD4+ T 161	  
cells (grey) and IFNγ+ Mtb-specific CD4+ T cells (red). (B) Expression of HLA-DR, Ki67 162	  
and CD38 on IFNγ+ Mtb-specific CD4+ T cells in LTBI/HIV- (n=16), aTB/HIV- (n=15), 163	  
LTBI /HIV+ (n=16) and aTB/HIV+ (n=18) participants. Open circles (!) depict LTBI 164	  
individuals, closed circles (") represent smear positive aTB patients and crosses (X) 165	  
correspond to smear negative and culture positive individuals with aTB. Horizontal lines 166	  
indicate the median. Statistical comparisons were performed using a non-parametric Mann-167	  
Whitney U test. (C) Receiver operator characteristics (ROC) curves and specificity/sensitivity 168	  
cross-over plots for HLA-DR expression level in IFNγ+ Mtb-specific CD4+ T cells to 169	  
discriminate between LTBI or aTB in HIV-uninfected and HIV-infected individuals. The 170	  
area-under-the-curve (AUC), p-value and confidence intervals (CI) are shown. The dotted line 171	  
depicts an AUC of 0.5, representing a random test. The vertical line on the cross-over plots 172	  
represents the optimal threshold to distinguish LTBI and aTB individuals.  173	  
 174	  
Figure 2. Comparison of the polyfunctional profile of ESAT-6/CFP-10-specific CD4+ T cells 175	  
between HIV-uninfected and HIV-infected individuals with latent or active TB disease. (A) 176	  
Representative dot plots of IFN-γ, TNF-α and IL-2 production in response to ESAT-6/CFP-10 177	  
peptide pool in one LTBI/HIV- individual. NS: No Stimulation. Numbers represent the 178	  
frequencies of cytokine-producing cells expressed as a percentage of the total CD4+ T cell 179	  
population. (B) Proportion of Mtb-specific CD4+ T cells producing any possible 180	  
combinations of IFN-γ, TNF-α or IL-2. Horizontal bars represent the median values and IQR. 181	  
Statistical analysis was performed using Mann-Whitney test and significant differences are 182	  
indicated by asterisks (***: p<0.001, **: p<0.01, *: p<0.05). Each slice of the pie corresponds 183	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to a distinct combination of cytokine. A key to colors used in the pie charts is shown at the 184	  
bottom of the graph. (C) Receiver operator characteristics (ROC) curves and 185	  
specificity/sensitivity cross-over plots for the proportion of IFNγ+IL2+TNFα+ (top panel) and 186	  
IFNγ+IL2-TNFα+ (bottom panel) Mtb-specific CD4+ T cells to discriminate between LTBI 187	  
or aTB in HIV-uninfected and HIV-infected individuals.  188	  
 189	  
Table S1:  190	  
Clinical characteristics of the study cohort. 191	  
 192	  
IQR: Interquatrile range, nd: not determined. 193	  
Groups n Female Age 
(years) 
Median 
[IQR] 
CD4 count 
(cells/mm3) 
Median [IQR] 
Previous 
TB 
Smear 
positive 
Culture 
positive 
LTBI/HIV- 17 8/17 
(47%) 
22  
[20-24] 
nd 1/17  
(6%) 
nd nd 
aTB/HIV- 17 5/17 
(29%) 
27  
[21-33] 
nd 3/16 
(19%) 
11/14 
(79%) 
13/14 
(93%) 
LTBI/HIV+ 21 14/21 
(67%) 
29  
[27-34] 
316 [231-543] 0/20  
(0%) 
0/17  
(0%) 
0/17  
(0%) 
aTB/HIV+ 21 12/21 
(57%) 
35  
[29-40] 
250 [155-295] 7/21 
(33%) 
8/21  
(38%) 
20/21 
(95%) 
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